Anthem Biosciences Limited CC-Feb26.pdf · 2026-02-05
Thanks for the opportunity. First is just a follow up on semaglutide. Are we focusing on the overall sema or the injectable version of semaglutide? Last quarter, I think we had said that process validation is underway. So, any timelines for filing DMF and have you signed any customers in India?
No, I understand it's the API, but the customers who have signed with us, will they be using it for oral or injectable? Do we have any visibility on that or we don't?